The most crucial lesson was that resilience cannot be forged on the day of crisis. In times of war or national crises, patients’ demand for essential medicines never ceases; therefore, pharmaceutical security cannot be measured merely by warehouse stock levels. True security is realized when the nation’s domestic production capacity remains uninterrupted under abnormal conditions. Wartime experience exposed existing vulnerabilities within the supply chain, which we must now decisively identify and mitigate.
Our absolute priority was safeguarding continuous manufacturing and keeping production lines fully operational. Our teams across all departments made exceptional efforts to sustain plant operations. In my view, one of the primary benchmarks of pharmaceutical maturity is the capacity to maintain production continuity under adversity. This experience proved invaluable for Parand Darou by charting a clear course toward reinforcing infrastructure and institutionalizing Business Continuity Plans (BCP).
Sanctions are not simply purchase restrictions; banking hurdles, foreign exchange transfers, logistics bottlenecks, and procurement barriers for specialized engineering parts drastically increase production risks and costs. Occasionally, a single minor component can halt an entire synthesis line. Hence, we must systematically diversify our supply chains and eliminate single-source dependencies.
Today’s primary challenge is not merely currency exchange rates, but operational access to foreign currency allocations, disciplined cost management, and securing adequate working capital aligned with inflating operational expenditures. When financing systems fail to keep pace with cost dynamics, liquidity pressures directly disrupt manufacturing schedules. Currency policies, commercial financing, and pricing frameworks must be viewed holistically.
It is extremely critical. API manufacturing involves complex, highly continuous chemical synthesis sequences; sudden power outages can instantly lead to batch loss, high wastage, and prolonged operational halts. Strategic facilities must receive targeted priority within national energy management schemes. Concurrently, industry leaders bear the duty of hardening their own infrastructures through rigorous preventive maintenance and backup utilities.
To mitigate downtime risks, we substantially fortified our electrical systems, HVAC and plant facilities, high-purity water generation, industrial utilities, and IT infrastructures. Every capital expenditure in a pharmaceutical plant must deliver three clear outcomes: production stability, operational risk reduction, and scalable capacity for growth.
It is extremely critical. API manufacturing involves complex, highly continuous chemical synthesis sequences; sudden power outages can instantly lead to batch loss, high wastage, and prolonged operational halts. Strategic facilities must receive targeted priority within national energy management schemes. Concurrently, industry leaders bear the duty of hardening their own infrastructures through rigorous preventive maintenance and backup utilities.
To mitigate downtime risks, we substantially fortified our electrical systems, HVAC and plant facilities, high-purity water generation, industrial utilities, and IT infrastructures. Every capital expenditure in a pharmaceutical plant must deliver three clear outcomes: production stability, operational risk reduction, and scalable capacity for growth.
Our goal is the strategic expansion and completion of our product portfolio. Every new molecule is selected based on clinical market demand, proprietary technological edge, supply chain security, and rigorous economic viability.
We ensured that manufacturing challenges and sanction-driven overhead did not derail our strategic expansion. Internal audits show domestic sales surged by approximately 210% over the audited twelve-month period compared to the previous timeframe. On the export front, despite tight constraints on controlled narcotic raw materials, our performance remained commendable. Furthermore, financial performance in the first four months of 1405 matched our total annual budget for 1404. However, I believe evaluating a manufacturing enterprise solely on top-line revenue is flawed. Profitability margins, revenue quality, cash flow stability, accounts receivable collection, working capital discipline, asset efficiency, and reinvestment capacity are equally vital. We do not pursue growth at any cost; growth must be sustainable and replicable.
Export expansion is an absolute imperative to achieve economies of scale and finance continuous R&D investments. Our roadmap transitions us from spot-export orders to an enduring, formalized presence in target regional markets. By integrating domestic chemical, petrochemical, and pharmaceutical value chains, we can secure a commanding market share across the region.
Entering the capital market represents far more than an avenue for capital raising. It institutionalizes superior financial transparency, strengthens corporate governance, and elevates reporting maturity. Our mission is to build an enterprise whose sustainable trajectory rests upon systematic corporate governance, rather than personalities.
The country requires a unified National Pharmaceutical Production Continuity Program for crisis conditions. This program must ensure uninterrupted energy supplies, agile access to foreign exchange facilities, and expedited regulatory decision-making mechanisms. Resilience is the synergistic outcome of policymaker, manufacturer, and supply chain alignment.
Pharmex must evolve from a conventional product showcase into a strategic platform for dialogue on crisis-resilient industrial architecture. If this exhibition bridges industrial manufacturers, academia, and regulatory bodies to catalyze technological innovation, capital investment, and supply chain de-risking, it transcends a trade event and becomes the driving engine of national pharmaceutical advancement. The core message of Pharmex this year is clear: crises must never halt progress; they must serve as catalysts for uncovering weaknesses and reinforcing critical infrastructures.
My message is direct: Pharmaceutical security cannot be built on the day of crisis; it must be engineered long before. The compounding trials of conflict, sanctions, and energy shortages prove that national resilience is not achieved simply by stockpiling finished dosage forms—it requires preserving active production capacity. Every manufacturing line kept alive, every high-purity API synthesized, and every engineering infrastructure that prevents plant shutdown is an integral pillar of national security. At Parand Darou, this remains our defining commitment: production stability, disciplined portfolio development, reinforced supply chains, and building an organization capable of enduring continuity. Our ultimate mandate is to ensure that even under the most formidable challenges, the lights across our nation’s vital production plants remain brightly lit.
